ZA200903553B - Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives - Google Patents

Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives

Info

Publication number
ZA200903553B
ZA200903553B ZA200903553A ZA200903553A ZA200903553B ZA 200903553 B ZA200903553 B ZA 200903553B ZA 200903553 A ZA200903553 A ZA 200903553A ZA 200903553 A ZA200903553 A ZA 200903553A ZA 200903553 B ZA200903553 B ZA 200903553B
Authority
ZA
South Africa
Prior art keywords
isoquinolinone derivatives
substituted isoquinolone
cycloalkylamine
cycloalkylamine substituted
rho
Prior art date
Application number
ZA200903553A
Other languages
English (en)
Inventor
Oliver Plettenburg
Armin Hofmeister
Jochen Goerlitzer
Matthias Loehn
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ZA200903553B publication Critical patent/ZA200903553B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
ZA200903553A 2006-12-27 2009-05-22 Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives ZA200903553B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06026895 2006-12-27

Publications (1)

Publication Number Publication Date
ZA200903553B true ZA200903553B (en) 2010-04-28

Family

ID=38069270

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903553A ZA200903553B (en) 2006-12-27 2009-05-22 Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives

Country Status (22)

Country Link
US (1) US20100056568A1 (enExample)
EP (1) EP2125744B1 (enExample)
JP (1) JP5318778B2 (enExample)
KR (1) KR20090103903A (enExample)
CN (1) CN101573338B (enExample)
AT (1) ATE505458T1 (enExample)
AU (1) AU2007338409B2 (enExample)
BR (1) BRPI0720710A2 (enExample)
CA (1) CA2673919C (enExample)
CO (1) CO6210725A2 (enExample)
DE (1) DE602007013950D1 (enExample)
DK (1) DK2125744T3 (enExample)
ES (1) ES2364511T3 (enExample)
IL (1) IL199536A (enExample)
MA (1) MA31023B1 (enExample)
MX (1) MX2009005828A (enExample)
MY (1) MY148514A (enExample)
NO (1) NO20092431L (enExample)
PT (1) PT2125744E (enExample)
RU (1) RU2009128688A (enExample)
WO (1) WO2008077553A1 (enExample)
ZA (1) ZA200903553B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470787B2 (en) 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
JP5235887B2 (ja) 2006-09-20 2013-07-10 アエリー ファーマシューティカルズ インコーポレイテッド Ｒｈｏキナーゼ阻害剤
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
AU2009262509B2 (en) * 2008-06-24 2014-01-30 Sanofi Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as Rho kinase inhibitors
AU2009262517B2 (en) * 2008-06-24 2014-01-09 Sanofi Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors
ES2436531T3 (es) * 2008-06-24 2014-01-02 Sanofi Isoquinolinas e isoquinolinonas sustituidas en posición 6
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010126626A2 (en) 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
EA019523B1 (ru) 2009-06-19 2014-04-30 Д. Вестерн Терапьютикс Инститьют, Инк. Производное замещенного изохинолина, содержащая его фармацевтическая композиция и применение для лечения заболеваний
CA2853466A1 (en) * 2011-10-26 2013-05-02 Emily A. Stein Agents, methods, and devices for affecting nerve function
PT3811943T (pt) 2013-03-15 2023-03-15 Aerie Pharmaceuticals Inc Composto para uso no tratamento de distúrbios oculares
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2016091731A1 (en) 2014-12-11 2016-06-16 Syngenta Participations Ag Pesticidally active tetracyclic derivatives with sulfur containing substituents
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
ES2705709T3 (es) 2014-12-24 2019-03-26 Gilead Sciences Inc Compuestos de isoquinolina para el tratamiento del VIH
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2017086941A1 (en) 2015-11-17 2017-05-26 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN112969694B (zh) 2018-11-09 2023-06-13 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其用途
CN110670090B (zh) * 2019-11-13 2021-06-29 广西师范大学 一种基于电化学合成异喹啉酮类化合物的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
WO2001053288A1 (en) * 2000-01-20 2001-07-26 Eisai Co., Ltd. Novel piperidine compounds and drugs containing the same
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
AU2003281623B8 (en) * 2002-07-22 2009-06-11 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative
AU2004276236B2 (en) * 2003-09-23 2008-01-24 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
WO2005035516A1 (ja) * 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. 新規縮合複素環化合物およびその用途
US7449477B2 (en) * 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
JP2005232175A (ja) * 2004-01-21 2005-09-02 Asahi Kasei Pharma Kk ５−置換イソキノリン医薬
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
ES2331853T3 (es) * 2005-06-28 2010-01-18 Sanofi-Aventis Derivados de isoquinolina como inhibidores de rho-cinasa.
US7618985B2 (en) * 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives

Also Published As

Publication number Publication date
HK1138583A1 (en) 2010-08-27
AU2007338409A1 (en) 2008-07-03
CO6210725A2 (es) 2010-10-20
BRPI0720710A2 (pt) 2014-12-23
KR20090103903A (ko) 2009-10-01
AU2007338409B2 (en) 2012-12-13
RU2009128688A (ru) 2011-02-10
CA2673919A1 (en) 2008-07-03
EP2125744A1 (en) 2009-12-02
WO2008077553A1 (en) 2008-07-03
DE602007013950D1 (de) 2011-05-26
CA2673919C (en) 2015-06-23
CN101573338A (zh) 2009-11-04
MA31023B1 (fr) 2009-12-01
MY148514A (en) 2013-04-30
EP2125744B1 (en) 2011-04-13
JP5318778B2 (ja) 2013-10-16
ATE505458T1 (de) 2011-04-15
NO20092431L (no) 2009-09-21
JP2010514718A (ja) 2010-05-06
MX2009005828A (es) 2009-06-16
IL199536A (en) 2014-07-31
DK2125744T3 (da) 2011-08-01
PT2125744E (pt) 2011-07-01
ES2364511T3 (es) 2011-09-05
CN101573338B (zh) 2013-03-20
US20100056568A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
MY148514A (en) Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives
TN2009000274A1 (en) Cycloalkylamine subsitututed isoquinoline and isoquinolinone derivatives
TN2009000269A1 (en) Cycloalkylamine substituted isoquinolone derivatives
TN2009000273A1 (en) New substituted isoquinoline and isoquinolinone derivatives
MY155279A (en) Substituted isoquinoline and isoquinolinone derivatives
TN2009000270A1 (en) Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
MY151953A (en) Cycloalkylamine substituted isoquinoline derivatives
TNSN08039A1 (en) Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
TNSN08038A1 (en) Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
TW200738678A (en) Isoquinoline derivatives
MY153615A (en) 6-substituted isoquinolines and isoquinolinones
TN2010000588A1 (en) Substituted isoquinolines and isoquinolinones